LOXO-305

DRUG4 trials

Sponsors

Eli Lilly and Company, Loxo Oncology, Inc.

Conditions

HealthyHealthy VolunteersLeukemia, Lymphocytic, Chronic, B-CellLeukemia, LymphoidLymphoma, B-CellLymphoma, B-Cell, Marginal ZoneLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell

Phase 1

Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants

CompletedNCT05134337

Loxo Oncology, Inc.Healthy Volunteers

Start: 2020-02-12End: 2020-10-30Updated: 2025-01-09

Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants

CompletedNCT05134350

Loxo Oncology, Inc.Healthy Volunteers

Start: 2020-02-06End: 2020-03-23Updated: 2025-01-10

A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants

CompletedNCT06180954

Eli Lilly and CompanyHealthy

Start: 2020-09-23End: 2020-11-06Updated: 2025-01-13

Phase 2

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

CompletedNCT04849416

Eli Lilly and CompanyLeukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Lymphoid, Lymphoma, B-Cell +4

Start: 2021-05-14End: 2025-12-29Updated: 2026-02-06

Related Papers

Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study

Blood2023-11-022 citations